Skip to main content

Table 2 Organ specific response rate in intrahepatic tumors and MVTT according to RECIST v1.1

From: Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

Response

INV

IIR

Intrahepatic (n = 58)

MVTT (n = 33)

P

Intrahepatic (n = 58)

MVTT (n = 33)

P

ORR, % (95% CI)

32.8 (21.0–46.3)

54.5 (36.4–71.9)

0.042

32.8 (21.0–46.3)

51.5 (33.5–69.2)

0.079

OSDCR, % (95% CI)

84.5 (72.6–2.7)

87.9 (71.8–96.6)

0.763

86.2 (74.6–93.9)

93.9 (79.8–99.3)

0.318

CR, % (n/N)

3.4 (2/58)

9.1 (3/33)

–

3.4 (2/58)

12.1 (4/33)

–

PR, % (n/N)

29.3 (17/58)

45.5 (15/33)

–

29.3 (17/58)

39.4 (13/33)

–

SD, % (n/N)

51.7 (30/58)

33.3 (11/33)

–

54.5 (31/58)

42.4 (14/33)

–

PD, % (n/N)

15.5 (9/58)

12.1 (4/33)

–

13.8 (8/58)

6.1 (2/33)

–

  1. CR complete response, IIR independent imaging review, INV investigator, MVTT macrovascular tumor thrombi, ORR objective response rate, OSDCR organ-specific disease control rate, PD progressive disease, PR partial response, SD stable disease